Latest Health News

EVE Health Group has partnered with telehealth provider hubMed to deliver a national patient support program, enhancing care continuity for users of its Dyspro and Libbo therapies.

Nufarm reported a mixed FY25 with strong crop protection profits offset by a statutory loss from seed restructuring, while targeting earnings growth and debt reduction in FY26.

Judo Capital Holdings Limited announces a fully franked quarterly distribution of AUD 1.79129 per Capital Note, reflecting a 7.1% annualised yield based on current market rates.

Sandon Capital Investments Limited has announced fully franked monthly dividends for the first quarter of 2026, offering investors an attractive annualised yield of 6.0%. The company’s strong profit reserves underpin its capacity to sustain dividend payments over the coming years.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

Technology One Limited has announced a combined ordinary and special dividend of AUD 0.30 per share, payable in December 2025, signaling steady shareholder returns.

TechnologyOne has reported a robust FY25 with profit before tax up 19% and ARR reaching $554.6 million, propelled by its SaaS+ platform and UK market expansion. The company sets an ambitious $1 billion ARR target by FY30, underpinned by strong R&D investment and AI integration.

Regis Healthcare reported robust FY25 financial results and outlined ambitious expansion plans targeting 10,000 beds by FY28, while urging urgent government reforms to address the sector’s undersupply of quality aged care.

Beacon Minerals Limited has announced a fully franked dividend distribution totaling AUD 0.05 per share, combining an ordinary and a special dividend, signaling steady shareholder returns.

Beacon Minerals has declared a fully franked dividend of $0.05 per share, reflecting its robust cash position and confidence in ongoing growth projects. The dividend combines a regular and special payout, signalling strong financial health amid advancing operations.

Tryptamine Therapeutics has enrolled its second patient in a pioneering clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with first dosing scheduled for December and results expected early next year.

Catapult Sports Ltd has reported a robust first half of FY26, with a 19% increase in Annualized Contract Value and a 50% jump in operating profit, driven by strategic acquisitions and strong SaaS growth.